Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in Combination with Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT05052970Phase 1Unknown
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in multiple myeloma (MM) (3 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoint: Treatment-emergent adverse events. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05052970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052970.